BioXcel Therapeutics
BTAI
44 hedge funds and large institutions have $29.4M invested in BioXcel Therapeutics in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 4 reducing their positions, and 2 closing their positions.
425% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 4
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
22% more funds holding
Funds holding: 36 → 44 (+8)
0.47% more ownership
Funds ownership: 1.2% → 1.66% (+0.47%)
10% less capital invested
Capital invested by funds: $32.6M → $29.4M (-$3.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$2.08M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.07M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.01M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.57M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$175K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$28.1K |
| 3 |
Citigroup
New York
|
-$13.7K |
| 4 |
Barclays
London,
United Kingdom
|
-$8.99K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$946 |
BTAI Hedge Fund Activity: Q3 2019 in Review
44 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2019, worth a combined $29.4M — down 9.7% from $32.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BTAI positions and 2 closed out — a net gain of 8 holders — while 21 added to existing stakes and 4 trimmed.
The largest buyer was Artemis Investment Management, adding an estimated $2.08M. The largest seller was Creative Planning, exiting entirely with an estimated $175K sold.
- 44 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2019, up from 36 in Q2 2019.
- Funds reported $29.4M of BioXcel Therapeutics stock for Q3 2019, down 9.7% quarter-over-quarter.
- 10 funds opened new BioXcel Therapeutics positions in Q3 2019 and 2 closed out, a net change of +8 holders.
- The largest BioXcel Therapeutics buyer in Q3 2019 was Artemis Investment Management, an estimated $2.08M added.
- The largest BioXcel Therapeutics seller in Q3 2019 was Creative Planning, an estimated $175K sold.
Based on aggregated 13F filings for Q3 2019.